Aracea Therapeutics

Menu

About Us

Aracea Therapeutics is an early-stage biotechnology company developing durable genetic-medicine approaches for metabolic diseases. Our work centers on restoring healthy energy balance by enhancing brown adipose tissue (BAT) biology and addressing key mechanisms that impair glucose regulation. We pursue a data-driven, mechanism-guided discovery framework that translates human biology into tractable therapeutic hypotheses with the potential for long-lasting benefit.

Who We Are

We are a multidisciplinary team spanning metabolism, translational science, and company building. Our experience covers discovery through preclinical planning across energy metabolism, adipose biology, mitochondrial function, assay development, and program execution. We are supported by advisors with recognized contributions to BAT research and metabolic disease.

What We Do

We study endogenous mechanisms observed in metabolically resilient individuals—people who maintain favorable energy balance and glycemic control across diverse dietary exposures—and seek to emulate these protective pathways in those with obesity, type 2 diabetes, and related metabolic disorders. Our near-term objective is to define and prioritize the most actionable BAT-centered mechanisms that can increase energy expenditure and improve metabolic control.

Our Scientific Approach

blank

Human Biology Anchored

We begin from convergent human evidence and peer-reviewed insight to identify protective metabolic mechanisms with clear therapeutic potential.

blank

Modality Fit for Mechanism

We remain modality-agnostic across gene therapy, genome editing, and genome regulation, aligning approach and delivery with the target biology.

blank

Milestone-Driven Translation

Current efforts focus on hypothesis refinement, assay robustness, and criteria for nominating lead concepts as development candidates, with subsequent phases designed to progress into in vivo evaluation and, ultimately, clinical studies.

Why BAT

blank

BAT uniquely converts chemical energy into heat, using glucose and fatty acids to support metabolic homeostasis. Greater BAT activity is associated with more favorable cardiometabolic profiles. By safely re-engaging this latent thermogenic capacity, we aim to durably increase energy expenditure and improve insulin sensitivity.

What We Bring

blank

Depth in Metabolism

Practical expertise in adipocyte biology, nutrient signaling, mitochondrial biogenesis, and biomarker strategy across molecular, cellular, and physiological readouts.

blank

Platform Versatility

The capability to pair target biology with the most appropriate genetic-medicine modality and delivery strategy.

blank

Execution Discipline

A capital-efficient, milestone-based plan emphasizing risk reduction, intellectual-property development, and partner-ready data packages.

Progress and Priorities

We are building the foundational evidence base to down-select high-value mechanisms and de-risk delivery assumptions. Workstreams include establishing human-relevant model systems, defining decision criteria for candidate nomination, and mapping the path to preclinical data packages aligned with partnership and investment milestones. A durable, limited-administration treatment paradigm remains a long-term objective, subject to future validation.

discover more

How We Work

We prioritize scientific rigor, patient impact, and safety. We collaborate selectively where external capabilities accelerate progress, while maintaining confidentiality around methods and procedures. We welcome discussions with partners and investors interested in BAT-centered genetic medicines for metabolic disease.